SCHEMBL6401909

SCHEMBL6401909

CC(=O)N(c1ccc(Oc2ccc3cc(O)ccc3c2)cc1)c1ccccc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.51
HCAR2 Q8TDS4 1/20 0.44
CASP3 P42574 2/20 0.44
NSD2 O96028 1/20 0.44
CASP7 P55210 1/20 0.44
CASP9 P55211 1/20 0.44
CASP6 P55212 1/20 0.44
CASP8 Q14790 1/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ESR1 P03372 5/20 0.43
NPC1 O15118 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
BCL2L1 Q07817 1/20 0.41
MCL1 Q07820 1/20 0.41
TSHR P16473 1/20 0.40
ESR2 Q92731 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6407413 0.92 MEN1 (0.52) PTPN1CASP3NSD2CASP7CASP9
SCHEMBL8044308 0.90 PTPN1 (0.45) PTPN1CASP3NSD2CASP7CASP9
SCHEMBL6404636 0.89 KMT2A (0.44) PTPN1HCAR2CASP3MEN1KMT2A
SCHEMBL6408806 0.80 ALOX5 (0.50) PTPN1MCL1
SCHEMBL8038284 0.80 ALDH1A1 (0.49) PTPN1PKM
SCHEMBL8027747 0.80 ALDH1A1 (0.47) PTPN1MEN1KMT2ABCL2L1MCL1
SCHEMBL28605602 0.79 PTPN1 (0.51) PTPN1CASP3NSD2CASP7CASP9
SCHEMBL6403207 0.78 TSPO (0.45) PTPN1MEN1KMT2AL3MBTL1ESR1
SCHEMBL8041238 0.78 LTA4H (0.51) PTPN1TSHR
SCHEMBL6340722 0.78 MAOB (0.44) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050027008-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredient TEIJIN LIMITED 2005-02-03 US disclosed
US-20030220402-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredients TEIJIN LIMITED (JP) 2003-11-27 US disclosed
EP-1256341-A1 CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT TEIJIN LIMITED (JP) 2002-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220402-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredients HCCS, BCOR, CBR1 PTPN1 504/4885HCAR2 274/4885CASP3 358/4885
US-20050027008-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredient CA9, HCCS, CA7 PTPN1 710/4885HCAR2 387/4885CASP3 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.